SecBot SecBot
3 ·Filed May 15, 2026

IBIO

iBio, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001104659-26-061762
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This is a routine insider onboarding filing with no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Stoner, which could provide insight into insider sentiment. No immediate action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
IBIO ▲ 0.00% at T+60d
NEUTRAL call 0.00% · α vs SPY -4.52% · entry $1.47 → $1.47
Entry = T+0 close
May 15, 2026
via day close
T+1d
-3.40%
call -3.40% · α -3.34%
$1.42
settled 5mo ago
T+5d
+25.17%
call +25.17% · α +24.21%
$1.84
settled 5mo ago
T+20d
+14.97%
call +14.97% · α +12.85%
$1.69
settled 4mo ago
T+60d
0.00%
call 0.00% · α -4.52%
$1.47
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. (IBIO), reporting no securities owned. The filing is a routine Section 16 compliance requirement for a new insider, accompanied by a limited power of attorney authorizing company officers to handle future filings. No material financial information, transactions, or changes in company operations are disclosed.

Key Facts

  • Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. on May 15, 2026, for the period ending May 7, 2026.
  • The filing reports zero beneficial ownership of iBio securities (1 class, 0 shares, 0 derivative securities).
  • A limited power of attorney (Exhibit 24) was executed, authorizing Dr. Martin B. Brenner and Marc Banjak to handle Section 16 filings on Stoner's behalf.
  • No transactions, equity awards, or changes in company operations are disclosed in the filing.

Financial Impact

No financial impact — the filing reports zero securities owned and no transactions.

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001104659-26-061762
Document: 0001104659-26-061762-index-headers.html0001104659-26-061762
Document: 0001104659-26-061762-index.html0001104659-26-061762
Document: 0001104659-26-061762.txt0001104659-26-061762
16 reports for IBIO
Performance horizon
60% Hit rate @ T+5 3 of 5 directional calls Went positive at some point 3 of 5 best @ T+20▲ +36.43%Feb 27, 2026
Filters
Rows
Reports for IBIO — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
8-K
NEUTRAL ★ 3/10
$0.8210awaiting T+5—$0.7100 (−13.52%)
Oct 14, 2026
12d ago
SC 13G
NEUTRAL ★ 4/10
$0.7808 $0.8400▲ +7.58%▲ +7.13%$0.7100 (−9.07%)
Oct 13, 2026
13d ago
8-K
BULLISH ★ 5/10
$0.7818 $0.8210▲ +5.01%▲ +6.17%$0.7100 (−9.18%)
Sep 14, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$1.19 $1.33▲ +11.76%▲ +9.64%$0.7100 (−40.34%)
Aug 28, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$1.36 $1.31▼ −3.68%▼ −3.79%$0.7100 (−47.79%)
Aug 28, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$1.36 $1.31▼ −3.68%▼ −3.79%$0.7100 (−47.79%)
Jul 1, 2026
16w ago
8-K
BULLISH ★ 6/10
$1.75 $1.59▼ −9.14%▼ −9.40%$0.7100 (−59.43%)
May 15, 2026
23w ago
3
NEUTRAL ★ 2/10
$1.47 $1.84▲ +25.17%▲ +24.21%$0.7100 (−51.70%)
May 12, 2026
23w ago
Press Release
BEARISH ★ 6/10
$1.55 $1.50▲ +3.23%▲ +2.07%$0.7100 (+54.19%)
May 8, 2026
24w ago
8-K
NEUTRAL ★ 2/10
$1.66 $1.42▼ −14.46%▼ −14.37%$0.7100 (−57.23%)
Showing 10 of 16

US Market Status

Market Closed — Opens in 6h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026